Therapeutic use of anti-CS1 antibodies
View Patent ↗The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
1. A method of treating myeloma, comprising administering to a patient suffering from myeloma but who has not developed clinical manifestations of myeloma, a therapeutically effective amount of a monoclonal anti-CS1 antibody or an anti-CS1 antigen binding fragment, wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment binds to a protein encoded by SEQ ID NO:1.
2. The method of claim 1 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment inhibits immunoglobulin secretion.
3. The method of claim 1 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is humanized.
4. The method of claim 1 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment induces antibody-dependent cellular cytotoxicity (“ADCC”) of cells expressing said protein encoded by SEQ ID NO:1.
5. The method of claim 4 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment induces at least 40% cytotoxicity of cells expressing said protein encoded by SEQ ID NO:1.
6. The method of claim 4 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment induces at least 60% cytotoxicity of cells expressing said protein encoded by SEQ ID NO:1.
7. The method of claim 1 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is an IgG 1 .
8. The method of claim 1 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment has a low level of or lacks fucose.
9. The method of claim 1 , further comprising administering to the patient an immunosuppressive drug.
10. The method of claim 1 , further comprising administering to the patient an immunodulator.
11. The method of claim 10 , further comprising administering to the patient an immunosuppressive drug.
12. The method of claim 9 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is administered after the immunosuppressive drug.
13. The method of claim 9 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is administered in combination with the immunosuppressive drug.
14. The method of claim 10 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is administered after the immunomodulator.
15. The method of claim 10 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is administered in combination with the immunomodulator.
16. The method of claim 11 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is administered after the immunosuppressive drug and the immunomodulator.
17. The method of claim 11 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is administered in combination with the immunosuppressive drug and the immunomodulator.
18. A method of treating myeloma, comprising administering to a patient suffering from myeloma but who has not developed clinical manifestations of myeloma, a therapeutically effective amount of a conjugate compound comprising a monoclonal anti-CS1 antibody or an anti-CS1 antigen binding fragment linked to an effector moiety, wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment binds to a protein encoded by SEQ ID NO:1.
19. The method of claim 18 , wherein the effector moiety is a cytotoxic agent.
20. The method of claim 18 , wherein the effector moiety is a detection moiety, an activatable moiety, a chemotherapeutic agent, a lipase, an antibiotic, a chemoattracting agent, an immune modulator or a radioisotope.
21. The method of claim 18 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment inhibits immunoglobulin secretion.
22. The method of claim 18 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is humanized.
23. The method of claim 18 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment induces antibody-dependent cellular cytotoxicity (“ADCC”) of cells expressing said protein encoded by SEQ ID NO:1.
24. The method of claim 23 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment induces at least 40% cytotoxicity of cells expressing said protein encoded by SEQ ID NO:1.
25. The method of claim 23 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment induces at least 60% cytotoxicity of cells expressing said protein encoded by SEQ ID NO:1.
26. The method of claim 18 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is an IgG 1 .
27. The method of claim 18 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment has a low level of or lacks fucose.
28. The method of claim 18 , further comprising administering to the patient an immunosuppressive drug.
29. The method of claim 18 , further comprising administering to the patient an immunodulator.
30. The method of claim 29 , further comprising administering to the patient an immunosuppressive drug.
31. The method of claim 28 , wherein the conjugate compound is administered after the immunosuppressive drug.
32. The method of claim 28 , wherein the conjugate compound is administered in combination with the immunosuppressive drug.
33. The method of claim 29 , wherein the conjugate compound is administered after the immunomodulator.
34. The method of claim 29 , wherein the conjugate compound is administered in combination with the immunomodulator.
35. The method of claim 30 , wherein the conjugate compound is administered after the immunosuppressive drug and the immunomodulator.
36. The method of claim 30 , wherein the conjugate compound is administered in combination with the immunosuppressive drug and the immunomodulator.